Antibodies to myelin oligodendrocyte glycoprotein (MOG) have been implicated in Multiple Sclerosis demyelination through activation of complement and/or macrophage-effector processes. We presented a novel mechanism, whereby MOG on oligodendrocytes, when cross-linked with anti-MOG and secondary antibody resulted in its repartitioning into lipid rafts, and changes in protein phosphorylation and morphology. Here, we show that similar events occur when anti-MOG is cross-linked with Fc receptors (FcRs) present on microglia but not with complement. These results indicate that FcRs are endogenous antigen/antibody cross-linkers in vitro, suggesting that FcRs could be physiologically relevant in vivo and possible targets for therapy in Multiple Sclerosis.
Introduction
Multiple Sclerosis (MS) is an inflammatory demyelinating disease affecting the central nervous system (CNS). It is characterized by areas of demyelination, often with associated axonal degeneration, causing severe, generally irreversible, functional consequences (Lassmann, 2004) . Inflammation is mediated by T cells, leading to local activation of microglia and impairment of the integrity of the blood brain barrier (Noseworthy et al., 2000) . In addition, B-cell responses are implicated in MS pathogenesis. For example, immunoglobulin deposits and opsonized myelin debris are detected at the active edge of demyelinating lesions (Genain et al., 1999; Lassmann, 2004; von Budingen et al., 2004) , and plasma exchange dramatically reduces clinical disease in a subset of patients (Kieseier and Hartung, 2003) . In particular, antibodies to myelin oligodendrocyte glycoprotein (MOG), a highly encephalitogenic glycoprotein exposed to the extracellular environment on the outer lamella of the myelin sheath (Linington et al., 1984) , are found in the cerebrospinal fluid and in disintegrating myelin around axons in lesions of acute MS patients (Genain et al., 1999) . Although there is still some controversy on the specificity of this antibody response in MS patients, the role of anti-MOG in those patients with pattern II demyelination has been clearly demonstrated (Lassmann et al., 2001) .
We have proposed a novel mechanism for anti-MOG-induced demyelination, wherein cross-linking MOG on the surface of oligodendrocytes (OLs) in culture with demyelinating antibodies against MOG followed by secondary cross-linking antibody, rapidly (minutes) and sequentially induces (a) repartitioning of MOG into detergent insoluble microdomains characteristic of lipid rafts, (b) alterations in the phosphorylation state of key proteins related to a cellular stress response and cytoskeletal instability, and (c) dramatic changes in cell morphology including a retraction of cell processes (without triggering cell death) (Marta et al., 2003; Marta et al., 2005a) . These results were observed by using either a monoclonal antibody against the extracellular domain of MOG (Marta et al., 2003; Marta et al., 2005a) or with pathogenic anti-MOGs purified from mice with a B-cell mediated EAE induced by immunization with human MOG, but not with non-pathogenic anti-MOGs from mice with a B-cell independent EAE induced by immunization with rat MOG (Marta et al., 2005b) . Recognizing the important implications of these data for understanding B-cell mediated disease in MS, we sought to identify endogenous activating cross-linkers of anti- Journal of Neuroimmunology 196 (2008) 35 -40 www.elsevier.com/locate/jneuroim
